BCL2 and cancer: Even in a BAX/BAK-competent scenario, cancer cells and senescent melanocytes that upregulate the expression of anti-apoptotic BCL-2 family members can also remain completely resistant to the senolytic effects of ABT-263/navitoclax and ABT-737/venetoclax [34].